503.HK Stock Analysis
50
Uncovered
Lansen Pharmaceutical Holdings Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Lansen Pharmaceutical Holdings Ltd. engages in the development, manufacture, and distribution of pharmaceuticals products. The company is headquartered in Ningbo, Zhejiang and currently employs 621 full-time employees. The company went IPO on 2010-05-07. The firm operates through three segments. Specialty Pharmaceuticals segment is engaged in the development, production and sales of specialty pharmaceuticals mainly used in the fields of rheumatology and dermatology. Its main specialty pharmaceutical products include pafulin, leflunomide tablets and mycophenolate mofetil dispersible tablets. Plant Extract and Healthcare Products segment is engaged in the development, production and sales of Chinese medicine extracts and healthcare products. Other Pharmaceuticals segment is engaged in businesses related to other pharmaceuticals.